Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Up 173.2% in May

by · The Cerbat Gem

Virax Biolabs Group Limited (NASDAQ:VRAX – Get Free Report) saw a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 391,277 shares, a growth of 173.2% from the April 30th total of 143,206 shares. Based on an average trading volume of 5,873,723 shares, the days-to-cover ratio is currently 0.1 days. Approximately 16.4% of the shares of the company are short sold.

Virax Biolabs Group Price Performance

VRAX opened at $0.19 on Monday. Virax Biolabs Group has a one year low of $0.10 and a one year high of $1.14. The stock’s fifty day moving average is $0.17 and its 200-day moving average is $0.27.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Virax Biolabs Group in a research report on Wednesday, April 8th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $1.00.

Read Our Latest Research Report on VRAX

About Virax Biolabs Group

(Get Free Report)

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.

Featured Articles